Table 2. Recurrence, Survival, and Sustained Recovery Rates in Phase 2 Treatment Conditions^a.

Treatment Condition	Phase 2 (N = 292)
	Recurrence Rate, %b	Survival Rate, %c	Sustained Recovery Rate, % (95% CI)d
Monotherapy
Monotherapy maintained (n = 68)	48.5	51.5	33.8 (25.1-42.5)
Monotherapy withdrawn (n = 69)	74.8	25.2	16.6 (9.7-23.5)
Combination therapy
Combination therapy maintained (n = 85)	48.5	51.5	38.7 (29.7-47.7)
Combination therapy withdrawn (n = 70)	76.7	23.3	17.6 (10.6-24.6)

^aPatients who met recovery criteria in phase 1 were eligible to participate in phase 2. Of the 452 patients eligible for phase 2, 155 of 227 (75.2%) from the combination therapy group and 137 of 225 (65.6%) from the monotherapy group provided consent to enter phase 2.⁸

^bRecurrence rates were estimated using Cox proportional hazards regression models. Estimates were calculated from survival analyses; therefore, numerator values were not available.

^cSurvival rates reflect 1 recurrence. Estimates were calculated from survival analyses; therefore, numerator values were not available.

^dEstimates of sustained recovery for the monotherapy maintained, monotherapy withdrawn, combination therapy maintained, and combination therapy withdrawn groups were calculated by prorating the estimates of nonrecurrence by the respective rates of recovery in phase 1.